Hypermethylation of the AKAP12 Promoter is a Biomarker of Barrett's-Associated Esophageal Neoplastic Progression

The A-kinase anchoring protein 12 (AKAP12) is a kinase scaffold protein with known tumor suppressor activity. Recently, AKAP12 promoter hypermethylation was reported in gastric and colorectal cancers. We examined AKAP12 promoter hypermethylation using real-time methylation-specific PCR in 259 human esophageal tissues. AKAP12 hypermethylation showed highly discriminative receiver-operator characteristic (ROC) curve profiles, clearly distinguishing esophageal adenocarcinoma (EAC) from esophageal squamous cell carcinoma and normal esophagus (P < 0.0001). AKAP12-normalized methylation values were significantly higher in Barrett's metaplasia (BE), dysplastic Barrett's, and EAC than in normal esophagus (P < 0.0000001). AKAP12 hypermethylation frequency was zero in normal esophagus but increased early during neoplastic progression, to 38.9% in BE from patients with Barrett's alone, 52.5% in dysplastic Barrett's metaplasia, and 52.2% in EAC. AKAP12 hypermethylation levels were significantly higher in normal esophageal epithelia from patients with EAC (mean = 0.00082) than in normal esophagi from patients without Barrett's or esophageal cancer (mean = 0.00007; P = 0.006). There was a significant correlation between AKAP12 hypermethylation and BE segment length, a known clinical neoplastic progression risk factor. In contrast, only 2 (7.7%) of 26 esophageal squamous cell carcinomas exhibited AKAP12 hypermethylation. Treatment of BIC and OE33 EAC cells with 5-aza-2'-deoxycytidine reduced AKAP12 methylation and increased AKAP12 mRNA expression. AKAP12 mRNA levels in EACs with unmethylated AKAP12 (mean = 0.1663) were higher than in EACs with methylated AKAP12 (mean = 0.0668). We conclude that promoter hypermethylation of AKAP12 is a common, tissue-specific event in human EAC, occurs early during Barrett's-associated esophageal neoplastic progression, and is a potential biomarker for the early detection of EAC. (Cancer Epidemiol Biomarkers Prev 2008;17(1):111–7)

[1]  L. Dubeau,et al.  Suppression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24-q25 , 1999, Oncogene.

[2]  Suna Wang,et al.  Hypermethylation of HPP1 is associated with hMLH1 hypermethylation in gastric adenocarcinomas. , 2002, Cancer research.

[3]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  G. Nuovo,et al.  Hypermethylation of the MLH1 Promoter With Concomitant Absence of Transcript and Protein Occurs in Small Patches of Crypt Cells in Unaffected Mucosa From Sporadic Colorectal Carcinoma , 2006, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[5]  I. Gelman.  The role of SSeCKS/gravin/AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development . , 2002, Frontiers in bioscience : a journal and virtual library.

[6]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[7]  P. Nelson,et al.  Isolation and characterization of a novel mitogenic regulatory gene, 322, which is transcriptionally suppressed in cells transformed by src and ras , 1995, Molecular and cellular biology.

[8]  Suna Wang,et al.  Hypermethylation of HPP 1 Is Associated with hMLH 1 Hypermethylation in Gastric Adenocarcinomas 1 , 2002 .

[9]  P. Unger,et al.  The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. , 2001, Cancer research.

[10]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[11]  B. Reid,et al.  Effect of Segment Length on Risk for Neoplastic Progression in Patients with Barrett Esophagus , 2000, Annals of Internal Medicine.

[12]  M. Bernstein,et al.  Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia , 2005, Anti-cancer drugs.

[13]  Hsien-yu Wang,et al.  Gravin-mediated Formation of Signaling Complexes in β2-Adrenergic Receptor Desensitization and Resensitization* , 2000, The Journal of Biological Chemistry.

[14]  Jun Yu,et al.  Concurrent hypermethylation of multiple tumor‐related genes in gastric carcinoma and adjacent normal tissues , 2001, Cancer.

[15]  E. Kuipers,et al.  Oesophageal cancer incidence and mortality in patients with long-segment Barrett's Oesophagus after a mean follow-up of 12.7 years , 2004, Scandinavian journal of gastroenterology.

[16]  Tae-You Kim,et al.  AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity , 2004, Oncogene.

[17]  M. Pepe,et al.  Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk , 2005, Oncogene.

[18]  R. Cherian,et al.  Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. , 1997, The American journal of gastroenterology.

[19]  R. Momparler.  Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine). , 2005, Seminars in oncology.

[20]  N. Matsubara,et al.  Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa , 2006, Gut.

[21]  John D. Scott,et al.  AKAP signalling complexes: focal points in space and time , 2004, Nature Reviews Molecular Cell Biology.

[22]  E. Somers.  International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[23]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[24]  R. Wong,et al.  Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. , 1999, Gastroenterology.

[25]  Li-dong Wang,et al.  Promoter hypermethylation and inactivation of O(6)-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines. , 2005, International journal of oncology.

[26]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[27]  Peter A. Jones,et al.  Roles of Cell Division and Gene Transcription in the Methylation of CpG Islands , 1999, Molecular and Cellular Biology.

[28]  Manel Esteller,et al.  Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. , 2003, Cancer research.

[29]  M. Bianchi,et al.  A large 6q deletion is a common cytogenetic alteration in fibroadenomas, pre-malignant lesions, and carcinomas of the breast. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  S. Kyo,et al.  Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers , 2003, Oncogene.

[31]  T. Motoyama,et al.  Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples , 2003, Oncogene.

[32]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[33]  Tetsuo Ito,et al.  A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. , 2006, Gastroenterology.

[34]  J. Trent,et al.  Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. , 1991, Cancer research.